These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 37435963)
21. Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations. Gremese E; Alivernini S; Ferraccioli ES; Ferraccioli G Clin Immunol; 2020 May; 214():108395. PubMed ID: 32240819 [TBL] [Abstract][Full Text] [Related]
22. [Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors]. Zhou J; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhang W; Zhang L Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):671-675. PubMed ID: 31650952 [TBL] [Abstract][Full Text] [Related]
23. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective. Steven NM; Fisher BA Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079 [TBL] [Abstract][Full Text] [Related]
24. Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity. Singh N; Hocking AM; Buckner JH Immunol Rev; 2023 Sep; 318(1):81-88. PubMed ID: 37493210 [TBL] [Abstract][Full Text] [Related]
25. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Kostine M; Rouxel L; Barnetche T; Veillon R; Martin F; Dutriaux C; Dousset L; Pham-Ledard A; Prey S; Beylot-Barry M; Daste A; Gross-Goupil M; Lallier J; Ravaud A; Forcade E; Bannwarth B; Truchetet ME; Richez C; Mehsen N; Schaeverbeke T; Ann Rheum Dis; 2018 Mar; 77(3):393-398. PubMed ID: 29146737 [TBL] [Abstract][Full Text] [Related]
26. Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy. Shen P; Deng X; Hu Z; Chen Z; Huang Y; Wang K; Qin K; Huang Y; Ba X; Yan J; Han L; Tu S Front Med (Lausanne); 2021; 8():762247. PubMed ID: 34805229 [TBL] [Abstract][Full Text] [Related]
27. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Cappelli LC; Gutierrez AK; Bingham CO; Shah AA Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1751-1763. PubMed ID: 27998041 [TBL] [Abstract][Full Text] [Related]
28. Checkpoint Molecules in Rheumatology-or the Benefits of Being Exhausted. Greisen SR; Deleuran B Curr Rheumatol Rep; 2021 Mar; 23(4):22. PubMed ID: 33651184 [TBL] [Abstract][Full Text] [Related]
29. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis. Kumar P; Saini S; Prabhakar BS Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481 [TBL] [Abstract][Full Text] [Related]
30. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update. Dang QM; Watanabe R; Shiomi M; Fukumoto K; Nobashi TW; Okano T; Yamada S; Hashimoto M Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982715 [TBL] [Abstract][Full Text] [Related]
35. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Mathias K; Rouhani S; Olson D; Bass AR; Gajewski TF; Reid P Oncologist; 2023 May; 28(5):440-448. PubMed ID: 36595378 [TBL] [Abstract][Full Text] [Related]
36. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Weinmann SC; Pisetsky DS Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080 [TBL] [Abstract][Full Text] [Related]
37. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Cappelli LC; Gutierrez AK; Baer AN; Albayda J; Manno RL; Haque U; Lipson EJ; Bleich KB; Shah AA; Naidoo J; Brahmer JR; Le D; Bingham CO Ann Rheum Dis; 2017 Jan; 76(1):43-50. PubMed ID: 27307501 [TBL] [Abstract][Full Text] [Related]
38. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. Calabrese C; Kirchner E; Kontzias A; Velcheti V; Calabrese LH RMD Open; 2017; 3(1):e000412. PubMed ID: 28405474 [TBL] [Abstract][Full Text] [Related]
39. An overview of immune checkpoint therapy in autoimmune diseases. Mohammadi P; Hesari M; Chalabi M; Salari F; Khademi F Int Immunopharmacol; 2022 Jun; 107():108647. PubMed ID: 35228033 [TBL] [Abstract][Full Text] [Related]
40. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer. Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]